Tudor Investment Corp ET AL raised its holdings in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) by 23.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 28,681 shares of the biotechnology company’s stock after purchasing an additional 5,458 shares during the period. Tudor Investment Corp ET AL owned 0.06% of Coherus BioSciences worth $412,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in CHRS. FMR LLC increased its stake in shares of Coherus BioSciences by 17.2% during the first quarter. FMR LLC now owns 7,671,981 shares of the biotechnology company’s stock valued at $162,262,000 after purchasing an additional 1,124,163 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Coherus BioSciences by 88.8% during the first quarter. Vanguard Group Inc. now owns 2,209,244 shares of the biotechnology company’s stock valued at $46,726,000 after purchasing an additional 1,039,402 shares in the last quarter. UBS Asset Management Americas Inc. increased its stake in shares of Coherus BioSciences by 54.5% during the second quarter. UBS Asset Management Americas Inc. now owns 1,391,216 shares of the biotechnology company’s stock valued at $19,964,000 after purchasing an additional 490,899 shares in the last quarter. JHL Capital Group LLC increased its stake in shares of Coherus BioSciences by 180.0% during the first quarter. JHL Capital Group LLC now owns 700,000 shares of the biotechnology company’s stock valued at $14,805,000 after purchasing an additional 450,000 shares in the last quarter. Finally, TIAA CREF Investment Management LLC increased its stake in shares of Coherus BioSciences by 70.6% during the second quarter. TIAA CREF Investment Management LLC now owns 1,001,104 shares of the biotechnology company’s stock valued at $14,366,000 after purchasing an additional 414,229 shares in the last quarter. 78.19% of the stock is owned by institutional investors and hedge funds.

In related news, insider Alan C. Herman sold 17,535 shares of the business’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $15.02, for a total transaction of $263,375.70. Following the completion of the transaction, the insider now owns 49,651 shares in the company, valued at approximately $745,758.02. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 26.28% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Tudor Investment Corp ET AL Has $412,000 Holdings in Coherus BioSciences, Inc. (CHRS)” was first posted by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/10/12/tudor-investment-corp-et-al-has-412000-holdings-in-coherus-biosciences-inc-chrs.html.

Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) opened at 14.30 on Thursday. Coherus BioSciences, Inc. has a 12 month low of $10.80 and a 12 month high of $31.48. The company’s 50 day moving average is $13.50 and its 200 day moving average is $16.26. The company’s market cap is $734.25 million.

Coherus BioSciences (NASDAQ:CHRS) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($1.08) EPS for the quarter, topping the consensus estimate of ($1.29) by $0.21. The firm had revenue of $1.40 million during the quarter. Coherus BioSciences had a negative net margin of 73.89% and a negative return on equity of 307.41%. On average, equities research analysts predict that Coherus BioSciences, Inc. will post ($5.13) EPS for the current fiscal year.

CHRS has been the subject of a number of analyst reports. BidaskClub downgraded shares of Coherus BioSciences from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 5th. Zacks Investment Research raised shares of Coherus BioSciences from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Tuesday, August 15th. ValuEngine raised shares of Coherus BioSciences from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $25.00 target price (down previously from $32.00) on shares of Coherus BioSciences in a research note on Tuesday, August 8th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $24.00 target price (down previously from $38.00) on shares of Coherus BioSciences in a research note on Wednesday, June 14th. Three analysts have rated the stock with a sell rating and nine have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $32.00.

Coherus BioSciences Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Want to see what other hedge funds are holding CHRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Coherus BioSciences, Inc. (NASDAQ:CHRS).

Institutional Ownership by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.